Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria

Infection and Immunity

Volumn 81, Issue 9, 2013, Pages 3317-3325

  Chilton, Paula M ^a   Hadelq, Diana M ^a   To, Thao T ^b   Mitchell, Thomas C ^a   Darveau, Richard P ^b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR 4;

ANTIBODY TITER; ARTICLE; BACTEROIDES THETAIOTAOMICRON; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; IMMUNE RESPONSE; NONHUMAN; PREVOTELLA INTERMEDIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VACCINATION;

EID: 84884246122     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01150-12     Document Type: Article

References (57)

1. Vella AT, McCormack JE, Linsley PS, Kappler JW, Marrack P. 1995. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2:261-270.
2. Skidmore BJ, Chiller JM, Morrison DC, Weigle WO. 1975. Immunologic properties of bacterial lipopolysaccharide (LPS): correlation between the mitogenic, adjuvant, and immunogenic activities. J. Immunol. 114:770-775.
3. Jacobs DM. 1979. Synergy between T cell-replacing factor and bacterial lipopolysaccharides (LPS) in the primary antibody response in vitro: a model for lipopolysaccharide adjuvant action. J. Immunol. 122:1421-1426.
4. Ribi E. 1984. Beneficial modification of the endotoxin molecule. J. Biol. Response Mod. 3:1-9.
5. Baldrick P, Richardson D, Elliott G, Wheeler AW. 2002. Safety evaluation of monophosphoryl lipidA(MPL): an immunostimulatory adjuvant. Regul. Toxicol. Pharmacol. 35:398-413.
6. Coats SR, Berezow AB, To TT, Jain S, Bainbridge BW, Banani KP, Darveau RP. 2011. The lipid A phosphate position determines differential host Toll-like receptor 4 responses to phylogenetically related symbiotic and pathogenic bacteria. Infect. Immun. 79:203-210.
7. Zähringer U, Salvetzki R, Wagner F, Lindner B, Ulmer AJ. 2001. Structural and biological characterisation of a novel tetra-acyl lipidAfrom Escherichia coli F515 lipopolysaccharide acting as endotoxin antagonist in human monocytes. J. Endotoxin Res. 7:133-146.
8. Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. 2002. Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect. Immun. 70:4092-4098.
9. Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC. 2009. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J. Biol. Chem. 284:31982-31991.
10. Embry CA, Franchi L, Nunez G, Mitchell TC. 2011. Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci. Signal. 4:ra28. doi:10.1126/scisignal.2001486.
11. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6:e16333. doi:10.1371/journal.pone.0016333.
12. Johnson AG, Tomai M, Solem L, Beck L, Ribi E. 1987. Characterization of a nontoxic monophosphoryl lipid A. Rev. Infect. Dis. 9(Suppl. 5):S512-S516.
13. Fujiwara T, Ogawa T, Sobue S, Hamada S. 1990. Chemical, immunobiological and antigenic characterizations of lipopolysaccharides from Bacteroides gingivalis strains. J. Gen. Microbiol. 136:319-326.
14. Mattsby-Baltzer I, Mielniczuk Z, Larsson L, Lindgren K, Goodwin S. 1992. Lipid A in Helicobacter pylori. Infect. Immun. 60:4383-4387.
15. Kumada H, Haishima Y, Umemoto T, Tanamoto K. 1995. Structural study on the free lipid A isolated from lipopolysaccharide of Porphyromonas gingivalis. J. Bacteriol. 177:2098-2106.
16. Isogai H, Isogai E, Fujii N, Oguma K, Kagota W, Takano K. 1988. Histological changes and some in vitro biological activities induced by lipopolysaccharide from Bacteroides gingivalis. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 269:64-77.
17. Reife RA, Coats SR, Al-Qutub M, Dixon DM, Braham PA, Billharz RJ, Howald WN, Darveau RP. 2006. Porphyromonas gingivalis lipopolysaccharide lipid A heterogeneity: differential activities of tetra- and pentaacylated lipid A structures on E-selectin expression and TLR4 recognition. Cell. Microbiol. 8:857-868.
18. Chen C, Coats SR, Bumgarner RE, Darveau RP. 2007. Hierarchical gene expression profiles of HUVEC stimulated by different lipid A structures obtained from Porphyromonas gingivalis and Escherichia coli. Cell. Microbiol. 9:1028-1038.
19. Coats SR, Reife RA, Bainbridge BW, Pham TT, Darveau RP. 2003. Porphyromonas gingivalis lipopolysaccharide antagonizes Escherichia coli lipopolysaccharide at toll-like receptor 4 in human endothelial cells. Infect. Immun. 71:6799-6807.
20. Mancuso G, Midiri A, Biondo C, Beninati C, Gambuzza M, Macri D, Bellantoni A, Weintraub A, Espevik T, Teti G. 2005. Bacteroides fragilisderived lipopolysaccharide produces cell activation and lethal toxicity via toll-like receptor 4. Infect. Immun. 73:5620-5627.
21. Munford RS. 2008. Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant? Infect. Immun. 76:454-465.
22. Cunningham MD, Seachord C, Ratcliffe K, Bainbridge B, Aruffo A, Darveau RP. 1996. Helicobacter pylori and Porphyromonas gingivalis lipopolysaccharides are poorly transferred to recombinant soluble CD14. Infect. Immun. 64:3601-3608.
23. Cunningham MD, Bajorath J, Somerville JE, Darveau RP. 1999. Escherichia coli and Porphyromonas gingivalis lipopolysaccharide interactions with CD14: implications for myeloid and nonmyeloid cell activation. Clin. Infect. Dis. 28:497-504.
24. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777-1782.
25. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316:1628-1632.
26. Thompson BS, Mata-Haro V, Casella CR, Mitchell TC. 2005. Peptidestimulated DO11.10 T cells divide well but accumulate poorly in the absence of TLR agonist treatment. Eur. J. Immunol. 35:3196-3208.
27. + T cells. J. Leukoc. Biol. 78:1273-1280.
28. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garçon N. 2009. AS04, an aluminum saltand TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183:6186-6197.
29. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877.
30. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17-27.
31. Barnden MJ, Allison J, Heath WR, Carbone FR. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76:34-40.
32. Al-Qutub MN, Braham PH, Karimi-Naser LM, Liu X, Genco CA, Darveau RP. 2006. Hemin-dependent modulation of the lipid A structure of Porphyromonas gingivalis lipopolysaccharide. Infect. Immun. 74:4474-4485.
33. Coats SR, Jones JW, Do CT, Braham PH, Bainbridge BW, To TT, Goodlett DR, Ernst RK, Darveau RP. 2009. Human Toll-like receptor 4 responses to P. 1-and 4' -phosphatase activities. Cell. Microbiol. 11:1587-1599.
34. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77-92.
35. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, Marrack P. 2009. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 183:4403-4414.
36. Marrack P, McKee AS, Munks MW. 2009. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9:287-293.
37. Deak E, Jayakumar A, Cho KW, Goldsmith-Pestana K, Dondji B, Lambris JD, McMahon-Pratt D. 2010. Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur. J. Immunol. 40:1355-1368.
38. Marrack P, Kappler J, Mitchell T. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521-530.
39. Thompson BS, Mitchell TC. 2004. Measurement of daughter cell accumulation during lymphocyte proliferation in vivo. J. Immunol. Methods 295:79-87.
40. Sengupta S, Jayaraman P, Chilton PM, Casella CR, Mitchell TC. 2007. Unrestrained glycogen synthase kinase-3β activity leads to activated T cell death and can be inhibited by natural adjuvant. J. Immunol. 178:6083-6091.
41. Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, Itano A, Pape KA. 2001. In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 19:23-45.
42. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. 2001. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410:101-105.
43. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. 2002. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3:354-359.
44. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT. 2012. Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci. Signal. 5:ra13. doi:10.1126/scisignal.2001963.
45. Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, Zielen S. 2010. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin. Exp. Immunol. 160:403-410.
46. Snapper CM, Paul WE. 1987. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944-947.
47. Snapper CM, Peschel C, Paul WE. 1988. IFN-γ stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J. Immunol. 140:2121-2127.
48. Khoruts A, Mondino A, Pape KA, Reiner SL, Jenkins MK. 1998. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187:225-236.
49. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174:4465-4469.
50. + T cell activation. Genes Cells 7:309-320.
51. Gandhapudi SK, Chilton PM, Mitchell TC. 2013. TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion. PLoS One 8:e56855. doi:10.1371/journal.pone.0056855.
52. Coban C, Ishii KJ, Uematsu S, Arisue N, Sato S, Yamamoto M, Kawai T, Takeuchi O, Hisaeda H, Horii T, Akira S. 2007. Pathological role of Toll-like receptor signaling in cerebral malaria. Int. Immunol. 19:67-79.
53. + T cell migration to the brain by IFN-γ during experimental cerebral malaria. Parasite Immunol. 30:544-553.
54. Brodskyn CI, Barral A, Boaventura V, Carvalho E, Barral-Netto M. 1997. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J. Immunol. 159:4467-4473.
55. + T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol. 31:432-439.
56. Wang ZE, Reiner SL, Hatam F, Heinzel FP, Bouvier J, Turck CW, Locksley RM. 1993. Targeted activation of CD8 cells and infection of 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J. Immunol. 151:2077-2086.
57. Gibson-Corley KN, Boggiatto PM, Mukbel RM, Petersen CA, Jones DE. 2010. A deficiency in the B cell response of C57BL/6 mice correlates with loss of macrophage-mediated killing of Leishmania amazonensis. Int. J. Parasitol. 40:157-161.